“Five months after a ‘breakthrough’ HIV prevention drug got approval in the United States and became available in many wealthy countries, it’s getting rolled out in two African countries hit especially hard by the disease.

On Wednesday, the U.S. State Department announced that Eswatini and Zambia have each received 500 doses of lenacapavir, a drug manufactured by Gilead Sciences that’s been hailed as by Science as a “breakthrough.” Just two injections a year provide near-complete protection against an HIV infection.

The delivered doses mark the first small step toward providing at least 2 million doses to the highest burden countries, largely in Africa, by 2028. That’s the goal of the Global Fund, a major donor to combating HIV, tuberculosis and malaria, along with Gilead Sciences and the State Department.”

From NPR.